Tuesday - June 9, 2026
Roche Announces Global Collaboration With Nurix Therapeutics to Co-develop and Co-commercialise Potential Best-in-class BTK Degrader Bexobrutideg Across Malignant Haematology, Immunology and Neurology
June 09, 2026
BASEL, Switzerland, June 9 -- Roche, a biotech company, issued the following news release on June 8, 2026:

* * *

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

* Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies

* Colla . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products